Troubling numbers from the Centers for Disease Control and Prevention (CDC) this week show nearly 3.5 million Americans are currently living with hepatitis C – many of which are unaware of their infection. Luckily, this chronic illness is treatable, but at a staggering cost. Read More
The Campaign for Sustainable Rx Pricing (CSRxP) kicked off the week with the introduction of its new policy platform aimed to curb skyrocketing prescription drug prices through increased transparency and competition which results in value. CSRxP’s solutions come at a critical time in the conversation about drug pricing, as this bipartisan issue garners unprecedented attention among policymakers, voters, and presidential candidates. Read More
Seven presidential candidates are still in the race heading into Super Tuesday and all of them are talking about rising prescription drug prices. While they differ in their solutions to this epidemic, candidates on both sides of the aisle agree that drug prices are rising at an unsustainable rate. Read More
Crippling drug prices have quickly become one of the hottest topics in health care. Consumers, patients, state budgets and public programs are feeling the burden, and reports show that we’re just getting started. Read More
Skyrocketing drug prices have been a hot issue on the presidential campaign trail. Candidates on both sides of the aisle are talking about the harmful impact these price tags have on Americans, and voters nationwide have been helping drive the conversation. Read More
Candidates on both sides of the aisle are talking about the harmful impact price tags have on Americans and the facts have been proven time after time: prescription drugs prices are simply out of control. Read More
A new survey from the Campaign for Sustainable Rx Pricing with polling conducted by Morning Consult shows voters in important early primary states, like Iowa, see prescription drug pricing as a hot-button, bipartisan political issue in the 2016 presidential election. Read More
Yesterday’s blockbuster earnings announcement from Gilead underscores how… Read More